357 related articles for article (PubMed ID: 14630678)
21. [Capecitabine].
Yamaguchi K; Shimamura T; Tada M
Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
[TBL] [Abstract][Full Text] [Related]
22. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
23. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
24. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Oshaughnessy JA; Blum J; Moiseyenko V; Jones SE; Miles D; Bell D; Rosso R; Mauriac L; Osterwalder B; Burger HU; Laws S
Ann Oncol; 2001 Sep; 12(9):1247-54. PubMed ID: 11697835
[TBL] [Abstract][Full Text] [Related]
25. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in dukes C colon cancer: results from the X-ACT trial.
Reddy GK
Clin Colorectal Cancer; 2004 Jul; 4(2):87-8. PubMed ID: 15285814
[No Abstract] [Full Text] [Related]
27. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
28. Capecitabine as adjuvant treatment for stage III colon cancer.
Twelves C; Wong A; Nowacki MP; Abt M; Burris H; Carrato A; Cassidy J; Cervantes A; Fagerberg J; Georgoulias V; Husseini F; Jodrell D; Koralewski P; Kröning H; Maroun J; Marschner N; McKendrick J; Pawlicki M; Rosso R; Schüller J; Seitz JF; Stabuc B; Tujakowski J; Van Hazel G; Zaluski J; Scheithauer W
N Engl J Med; 2005 Jun; 352(26):2696-704. PubMed ID: 15987918
[TBL] [Abstract][Full Text] [Related]
29. Potential regional differences for the tolerability profiles of fluoropyrimidines.
Haller DG; Cassidy J; Clarke SJ; Cunningham D; Van Cutsem E; Hoff PM; Rothenberg ML; Saltz LB; Schmoll HJ; Allegra C; Bertino JR; Douillard JY; Gustavsson BG; Milano G; O'Connell M; Rustum Y; Tabernero J; Gilberg F; Sirzén F; Twelves C
J Clin Oncol; 2008 May; 26(13):2118-23. PubMed ID: 18445840
[TBL] [Abstract][Full Text] [Related]
30. 5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer.
Seitz JF
Semin Oncol; 2001 Feb; 28(1 Suppl 1):41-4. PubMed ID: 11273590
[TBL] [Abstract][Full Text] [Related]
31. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.
Wolmark N; Rockette H; Mamounas E; Jones J; Wieand S; Wickerham DL; Bear HD; Atkins JN; Dimitrov NV; Glass AG; Fisher ER; Fisher B
J Clin Oncol; 1999 Nov; 17(11):3553-9. PubMed ID: 10550154
[TBL] [Abstract][Full Text] [Related]
32. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ
J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294
[TBL] [Abstract][Full Text] [Related]
33. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Twelves CJ; Butts CA; Cassidy J; Conroy T; Braud Fd; Diaz-Rubio E; Tabernero JM; Schoffski P; Figer A; Brunet R; Grossmann J; Sobrero AF; Van Cutsem EJ
Clin Colorectal Cancer; 2005 Jul; 5(2):101-7. PubMed ID: 16098250
[TBL] [Abstract][Full Text] [Related]
34. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
36. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Ward S; Kaltenthaler E; Cowan J; Brewer N
Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
[TBL] [Abstract][Full Text] [Related]
37. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
[TBL] [Abstract][Full Text] [Related]
38. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
[TBL] [Abstract][Full Text] [Related]
39. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Marsé H; Van Cutsem E; Grothey A; Valverde S
Eur J Oncol Nurs; 2004; 8 Suppl 1():S16-30. PubMed ID: 15341879
[TBL] [Abstract][Full Text] [Related]
40. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
